198 related articles for article (PubMed ID: 1444883)
1. Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.
Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
Arch Neurol; 1992 Nov; 49(11):1161-7. PubMed ID: 1444883
[TBL] [Abstract][Full Text] [Related]
2. A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease.
Grafton ST; Mazziotta JC; Pahl JJ; St George-Hyslop P; Haines JL; Gusella J; Hoffman JM; Baxter LR; Phelps ME
Ann Neurol; 1990 Nov; 28(5):614-21. PubMed ID: 1979723
[TBL] [Abstract][Full Text] [Related]
3. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
[TBL] [Abstract][Full Text] [Related]
4. Normal caudate glucose metabolism in persons at risk for Huntington's disease.
Young AB; Penney JB; Starosta-Rubinstein S; Markel D; Berent S; Rothley J; Betley A; Hichwa R
Arch Neurol; 1987 Mar; 44(3):254-7. PubMed ID: 2950844
[TBL] [Abstract][Full Text] [Related]
5. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.
Mazziotta JC; Phelps ME; Pahl JJ; Huang SC; Baxter LR; Riege WH; Hoffman JM; Kuhl DE; Lanto AB; Wapenski JA
N Engl J Med; 1987 Feb; 316(7):357-62. PubMed ID: 2949152
[TBL] [Abstract][Full Text] [Related]
6. Psychiatric, genetic, and positron emission tomographic evaluation of persons at risk for Huntington's disease.
Baxter LR; Mazziotta JC; Pahl JJ; Grafton ST; St George-Hyslop P; Haines JL; Gusella JF; Szuba MP; Selin CE; Guze BH
Arch Gen Psychiatry; 1992 Feb; 49(2):148-54. PubMed ID: 1532304
[TBL] [Abstract][Full Text] [Related]
7. Cerebral metabolism of glucose in benign hereditary chorea.
Suchowersky O; Hayden MR; Martin WR; Stoessl AJ; Hildebrand AM; Pate BD
Mov Disord; 1986; 1(1):33-44. PubMed ID: 2973557
[TBL] [Abstract][Full Text] [Related]
8. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease.
Hayden MR; Hewitt J; Stoessl AJ; Clark C; Ammann W; Martin WR
Neurology; 1987 Sep; 37(9):1441-7. PubMed ID: 2957611
[TBL] [Abstract][Full Text] [Related]
9. Single photon emission computed tomographic blood flow and magnetic resonance volume imaging of basal ganglia in Huntington's disease.
Harris GJ; Aylward EH; Peyser CE; Pearlson GD; Brandt J; Roberts-Twillie JV; Barta PE; Folstein SE
Arch Neurol; 1996 Apr; 53(4):316-24. PubMed ID: 8929153
[TBL] [Abstract][Full Text] [Related]
10. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease.
Kuhl DE; Metter EJ; Riege WH; Markham CH
Ann Neurol; 1984; 15 Suppl():S119-25. PubMed ID: 6234856
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in the early diagnosis of Huntington's disease.
Hayden MR; Martin WR; Stoessl AJ; Clark C; Hollenberg S; Adam MJ; Ammann W; Harrop R; Rogers J; Ruth T
Neurology; 1986 Jul; 36(7):888-94. PubMed ID: 2940474
[TBL] [Abstract][Full Text] [Related]
12. Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease.
Aylward EH; Codori AM; Rosenblatt A; Sherr M; Brandt J; Stine OC; Barta PE; Pearlson GD; Ross CA
Mov Disord; 2000 May; 15(3):552-60. PubMed ID: 10830423
[TBL] [Abstract][Full Text] [Related]
13. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan.
Kuhl DE; Phelps ME; Markham CH; Metter EJ; Riege WH; Winter J
Ann Neurol; 1982 Nov; 12(5):425-34. PubMed ID: 6217782
[TBL] [Abstract][Full Text] [Related]
14. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline.
Young AB; Penney JB; Starosta-Rubinstein S; Markel DS; Berent S; Giordani B; Ehrenkaufer R; Jewett D; Hichwa R
Ann Neurol; 1986 Sep; 20(3):296-303. PubMed ID: 2945510
[TBL] [Abstract][Full Text] [Related]
15. Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease.
Kuhl DE; Markham CH; Metter EJ; Riege WH; Phelps ME; Mazziotta JC
Res Publ Assoc Res Nerv Ment Dis; 1985; 63():199-209. PubMed ID: 3161165
[TBL] [Abstract][Full Text] [Related]
16. Caudate glucose hypometabolism in a subject carrying an unstable allele of intermediate CAG(33) repeat length in the Huntington's disease gene.
Squitieri F; Esmaeilzadeh M; Ciarmiello A; Jankovic J
Mov Disord; 2011 Apr; 26(5):925-7. PubMed ID: 21370274
[No Abstract] [Full Text] [Related]
17. Multimodal imaging biomarkers in premanifest and early Huntington's disease: 30-month IMAGE-HD data.
D JF; Stout JC; Poudel G; Churchyard A; Chua P; Egan GF; Georgiou-Karistianis N
Br J Psychiatry; 2016 Jun; 208(6):571-8. PubMed ID: 26678864
[TBL] [Abstract][Full Text] [Related]
18. [SPECT studies with 99mTc-HMPAO in Huntington's chorea patients].
Botsch H; Oepen G; Deuschl G; Wolff G
Rofo; 1987 Dec; 147(6):666-8. PubMed ID: 2827263
[TBL] [Abstract][Full Text] [Related]
19. Single photon emission computed tomography in Huntington's chorea.
Leblhuber F; Hoell K; Reisecker F; Gebetsberger B; Puehringer W; Trenkler E; Deisenhammer E
Psychiatry Res; 1989 Sep; 29(3):337-9. PubMed ID: 2532751
[No Abstract] [Full Text] [Related]
20. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease.
Holthoff VA; Koeppe RA; Frey KA; Penney JB; Markel DS; Kuhl DE; Young AB
Ann Neurol; 1993 Jul; 34(1):76-81. PubMed ID: 8390806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
